Levitra Product Information
Product name:
Levitra (Vardenafil HCL) - Each tablet contains 5 mg, 10 mg or 20 mg of vardenafil (as hydrochloride tri hydrate).
Drug Class
Levitra is an oral treatment (pill) for Erectile Dysfunction and is classed as a phosphoresce inhibitor that works by helping the blood flow into the penis to achieve and maintain an erection.
Pharmaceutical Form
Levitra is a film coated orange round tablet marked with the BAYER-cross on one side and 5,10 or 20 on the other side. PP/Aluminium foil blisters in cartons of 2, 4, 8 and 12 tablets.
Levitra Dosage and Administration
For most patients, the recommended starting dose of LEVITRA is 10 mg. Levitra is taken orally approximately 1 hour before the sexual activity. The dose may be increased to a maximum recommended dose of 20 mg or decreased to 5 mg based on efficacy and side effects. LEVITRA pill can be taken with or without food. The maximum recommended dosing frequency of Levitra is once per day.
sexual stimulation is needed for an erection to occur with Levitra. Levitra does not create sex desire. Levitra is not for women.
Levitra Storage
Store Levitra at 25 degrees C (77 degrees F). The excursions are permitted 15-30 degrees C (59-86 degrees F).
Levitra Contraindications
Nitrates
Administration of LEVITRA with nitrates (either regularly and/or intermittently) and nitric oxide donors is contraindicated. Consistent with the effects of PDE5 inhibition on the nitric oxide/cyclic guanosine mono phosphate pathway, PDE5 inhibitors may potentiate the hypotensive effects of nitrates.
Hypersensitivity
Levitra is contraindicated for patients with a known hypersensitivity to any component of the tablet.
Loss of Vision because of NAION
Levitra is contraindicated in patients who have loss of vision in one eye because of non-arteritic anterior ischemic optic neuropathy (NAION).
Levitra is not recommended in patients with severe cardiovascular disorders
Levitra should generally not be used in men for whom sexual activity is inadvisable (e.g. patients with severe cardiovascular disorders such as unstable angina or severe cardiac failure)
for more information please see the following patient information leaflets: